Cassava's Simufilam: Safe On The Outside, Scrambled On The Inside [Seeking Alpha]
Cassava Sciences, Inc. (SAVA)
Last cassava sciences, inc. earnings: 8/12 08:30 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Follow Play 11min Summary The third interim safety review for simufilam showed no significant safety concerns, particularly regarding amyloid-related imaging abnormalities (ARIAs). Despite interim safety results, simufilam's efficacy remains unproven, with no statistically significant improvements in cognitive measures in recent trials. Data integrity concerns persist, especially after compromised biomarker results from the Phase 2b study and the fraud indictment of a former key collaborator. Cassava faces a cash burn of $80-$90 million in the second half of 2024, which will significantly reduce its current cash runway. Due to data integrity issues and unproven efficacy, I maintain a "strong sell" recommendation, as the stock could collapse without favorable Phase 3 results. Richard Drury Introduction Cassava Sciences' NASDAQ: SAVA ) stock remains volatile ahead of critical Phase 3 data for their Alzheimer's candidate, simufilam. My previous articles focused on
Show less
Read more
Impact Snapshot
Event Time:
SAVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAVA alerts
High impacting Cassava Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
SAVA
News
- Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
- Cassava Sciences Appoints Freda Nassif as Chief Commercial OfficerGlobeNewswire
- Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- What Makes Cassava Sciences (SAVA) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Cassava Sciences, Inc. (NASDAQ: SAVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $116.00 price target on the stock.MarketBeat
SAVA
Earnings
- 11/7/24 - Beat
SAVA
Sec Filings
- 11/20/24 - Form 4
- 11/20/24 - Form 3
- 11/20/24 - Form 4
- SAVA's page on the SEC website